Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Yejiang Zhu"'
Autor:
Shangying Hu, Xiaoqian Xu, Fengcai Zhu, Ying Hong, Yuemei Hu, Xun Zhang, Qinjing Pan, Wenhua Zhang, Chengfu Zhang, Xiaoping Yang, Jiaxi Yu, Jiahong Zhu, Yejiang Zhu, Feng Chen, Shuang Zhao, Naveen Karkada, Haiwen Tang, Dan Bi, Frank Struyf, Fanghui Zhao
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 4, Pp 955-964 (2021)
Human papillomavirus (HPV) vaccines are efficacious against HPV infections and associated lesions in women HPV-naïve at vaccination. However, vaccine efficacy (VE) against oncogenic, high-risk HPV (HR-HPV) types in women infected with any other HR-H
Externí odkaz:
https://doaj.org/article/a714e90d323d46e2bac37315b739bea5
Autor:
Feng‐Cai Zhu, Shang‐Ying Hu, Ying Hong, Yue‐Mei Hu, Xun Zhang, Yi‐Ju Zhang, Qin‐Jing Pan, Wen‐Hua Zhang, Fang‐Hui Zhao, Cheng‐Fu Zhang, Xiaoping Yang, Jia‐Xi Yu, Jiahong Zhu, Yejiang Zhu, Feng Chen, Qian Zhang, Hong Wang, Changrong Wang, Jun Bi, Shiyin Xue, Lingling Shen, Yan‐Shu Zhang, Yunkun He, Haiwen Tang, Naveen Karkada, Pemmaraju Suryakiran, Dan Bi, Frank Struyf
Publikováno v:
Cancer Medicine, Vol 8, Iss 14, Pp 6195-6211 (2019)
Abstract Background Cervical cancer is a major public health concern in China. We report the end‐of‐study results of a phase II/III trial to assess the efficacy, immunogenicity, and safety of the AS04‐human papillomavirus (HPV)‐16/18 vaccine
Externí odkaz:
https://doaj.org/article/7eafe7b507044933b700ba50d3514abc
Autor:
Fanghui Zhao, Archana Jastorff, Ying Hong, Shangying Hu, Wen Chen, Xiaoqian Xu, Yejiang Zhu, Jiahong Zhu, Xun Zhang, Wenhua Zhang, Dacheng Xu, Dali Wang, Rong Tang, Yonghong Sun, Yiping Shen, Qinjing Pan, Jian Yin, Daokuan Liu, Bin Liu, Naveen Karkada, Chunmei Jiang, Jianfeng Cui, Feng Chen, Jun Bi, Yuqing Bao, Xin Zhou, Cyrille Cartier, Yuemei Hu, Dorota Borys
Publikováno v:
Asia-Pacific Journal of Clinical Oncology.
The pivotal efficacy study assessed efficacy and safety of GSK's AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years up to 6 years. The present extension study, performed 4 years later, offered AS04-HPV-16/18 vaccination to placebo recipients. V
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f6b53a9c7bae9ed2c83ee529bc9eb68
https://doi.org/10.1111/ajco.13833
https://doi.org/10.1111/ajco.13833
Autor:
Fengcai Zhu, Qin-Jing Pan, Jia-Xi Yu, Frank Struyf, Ying Hong, Yunkun He, Shang-Ying Hu, Naveen Karkada, Yuemei Hu, Yi-Ju Zhang, Yan-Shu Zhang, Xiaoping Yang, Haiwen Tang, Cheng-Fu Zhang, Feng Chen, P.V. Suryakiran, Dan Bi, Jun Bi, Changrong Wang, Fang-Hui Zhao, Xun Zhang, Lingling Shen, Qian Zhang, Hong Wang, Shiyin Xue, Wen-hua Zhang, Jiahong Zhu, Yejiang Zhu
Publikováno v:
Cancer Medicine, Vol 8, Iss 14, Pp 6195-6211 (2019)
Cancer Medicine
Cancer Medicine
Background Cervical cancer is a major public health concern in China. We report the end‐of‐study results of a phase II/III trial to assess the efficacy, immunogenicity, and safety of the AS04‐human papillomavirus (HPV)‐16/18 vaccine in Chines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fbb9c7a6d11b1188bbc67713fad16f4
https://doaj.org/article/7eafe7b507044933b700ba50d3514abc
https://doaj.org/article/7eafe7b507044933b700ba50d3514abc
Autor:
Ying Hong, Haiwen Tang, Fengcai Zhu, Shang-Ying Hu, Qin-Jing Pan, Cheng-Fu Zhang, Yuemei Hu, Xiaoping Yang, Xiaoqian Xu, Feng Chen, Fang-Hui Zhao, Dan Bi, Jia-Xi Yu, Shuang Zhao, Wen-hua Zhang, Jiahong Zhu, Yejiang Zhu, Xun Zhang, Frank Struyf, Naveen Karkada
Publikováno v:
Human Vaccines & Immunotherapeutics
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Human papillomavirus (HPV) vaccines are efficacious against HPV infections and associated lesions in women HPV-naïve at vaccination. However, vaccine efficacy (VE) against oncogenic, high-risk HPV (HR-HPV) types in women infected with any other HR-H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e8ea745bcf9383e0c0501946e7a59e8
https://pubmed.ncbi.nlm.nih.gov/33180670
https://pubmed.ncbi.nlm.nih.gov/33180670
Autor:
Ying Hong, Yunkun He, Yi-Ju Zhang, Dan Bi, Yuemei Hu, Jun Bi, Haiwen Tang, Shiyin Xue, Fang-Hui Zhao, P.V. Suryakiran, Xun Zhang, Jia-Xi Yu, Xiaoping Yang, Frank Struyf, Lingling Shen, Qian Zhang, Shang-Ying Hu, Naveen Karkada, Qin-Jing Pan, Fengcai Zhu, Changrong Wang, Cheng-Fu Zhang, Feng Chen, Yan-Shu Zhang, Yejiang Zhu, Wen-hua Zhang, Jiahong Zhu, Hong Wang
Publikováno v:
Cancer Medicine
We previously reported the results of a phase II/III, double‐blind, randomized controlled study in Chinese women (NCT00779766) showing a 94.2% (95% confidence interval: 62.7–99.9) HPV‐16/18 AS04‐adjuvanted vaccine efficacy (VE) against cervic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::244ce44ae28d6f0278a6109d56e7336d
http://europepmc.org/articles/PMC5269697
http://europepmc.org/articles/PMC5269697